<DOC>
	<DOCNO>NCT00560547</DOCNO>
	<brief_summary>This single arm study ass long-term maintenance hemoglobin level , safety tolerability once-monthly intravenous administration Mircera hemodialysis patient chronic renal anemia . Patients currently receive darboepoetin alfa epoetin alfa maintenance treatment receive intravenous Mircera start dose 120 , 200 360 micrograms/4 week ( base ESA dose administer week-1 ) . Subsequent dos adjust maintain hemoglobin level within target range 10.5-12.5g/dL . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Once-Monthly Intravenous Mircera Hemodialysis Patients With Chronic Renal Anemia .</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; chronic renal anemia ; regular longterm hemodialysis therapy mode dialysis &gt; =3 month ; continuous iv sc maintenance ESA treatment previous 2 month . transfusion red blood cell previous 2 month ; significant acute chronic bleeding , overt gastrointestinal bleeding ; active malignant disease ( except nonmelanoma skin cancer ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>